Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 235

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 235
---
 comparable companies or our industry generally; 

•our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; 

•speculation in the press or investment community; 

•share price and fluctuations of trading volume of our common stock;

•the impact of interest rate increases on the overall stock market and the market for biopharmaceutical company stocks;

•fluctuations in the valuation of companies perceived by investors to be comparable to us; 

•sales of shares of our common stock by us, insiders or our stockholders; 

•our ability or inability to raise additional capital and the terms on which we raise it; 

•the concentrated ownership of our common stock; 

•changes in accounting principles; 

•natural disasters and other calamities;

•general economic, industry and market conditions, including inflation, changes in interest rates and significant political, trade or regulatory developments, many of which are beyond our control;

100

•other events or factors, including those resulting from global pandemics, such as the COVID-19 pandemic, or war, incidents of terrorism or responses to these events, including global regional conflicts; and

•cybersecurity incidents.

In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations, including as a result of the COVID-19 pandemic, increase in inflation and changes in interest rates, as well as disruptions to the supply chain, that have been often unrelated or disproportionate to the operating performance of the issuer. Furthermore, the trading price of our common stock may be adversely affected by third parties trying to drive down the market price. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock declines and their activities can negatively affect our stock price. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock. 

In the past, securities class action litigation has often been brought against public companies following declines in the market price of their securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and